(Q58041468)

English

Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease

scientific article published on 01 May 2000

  • Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease

Statements

Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease (English)
0 references
Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease (English)
Silvia Montoto
0 references
Mireia Cam�s
0 references
Armando L�pez-Guillermo
0 references
Francesc Bosch
0 references
Francisco Cervantes
0 references
Joan Blad�
0 references
Jordi Esteve
0 references
Francesc Cobo
0 references
Benet Nomdedeu
0 references
El�as Campo
0 references
Emilio Montserrat
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit